Two peptides have done more than any others to make repair and recovery a working clinical category: BPC-157 and TB-500 (TB4-Frag). Together they account for a sizable share of the integrative peptide conversation. They also account for many of the missteps clinicians new to peptide therapy make in their first year of prescribing.
Used with care, both peptides earn their place. Used reflexively, they get credit for healing that would have happened anyway, and they get blame for outcomes they were never the right tool for.
What BPC-157 actually does
BPC-157, body protection compound, is a synthetic pentadecapeptide derived from a protective sequence in human gastric juice. Its most consistent clinical signal is in the gut, where it stabilizes mucosal integrity and supports healing of ulcerated or inflamed tissue. Beyond the gut, the literature points to angiogenic effects, modulation of nitric oxide signaling, and support for tendon, ligament, and soft-tissue repair.
What BPC-157 is not is a generic anti-inflammatory or a substitute for surgical or structural correction. The clinician using it well is the one matching it to a tissue and a mechanism, not pasting it onto every recovery protocol.
What TB-500 actually does
TB-500, a synthetic fragment of thymosin beta-4, drives cell migration and recruitment to sites of injury. Its strength is in promoting the orderly arrival of repair machinery rather than directly building tissue. Clinically it is paired with BPC-157 when the goal is to combine local tissue stabilization with systemic repair signaling.
In musculoskeletal recovery the pairing is common enough that many clinicians prescribe them together by default. The patients who benefit most are the ones with a defined injury, an intact rehabilitation plan, and the time to let the biology do its work.
Sequencing matters more than dose
The single most useful idea in repair peptide work is sequencing. Tissue heals in phases: inflammation, proliferation, remodeling. Each phase has its own signaling priorities. Loading a patient with repair peptides while they are still in acute inflammation without addressing the inflammatory driver is a waste. So is continuing them deep into remodeling when load and movement are the real medicine.
Most protocols benefit from a defined arc: an initiation phase, a working phase, and an exit. Indefinite use is rarely the answer.
"Tissue heals in phases. Each phase has its own signaling priorities."
Clinical pitfalls to avoid
Three pitfalls show up repeatedly. First, treating soft-tissue symptoms in patients whose real problem is biomechanical: a torn rotator cuff does not become whole because of a peptide. Second, prescribing repair peptides on top of unaddressed systemic inflammation. The patient feels better briefly, then plateaus. Third, ignoring the gut. If the gastrointestinal lining is compromised, systemic repair is fighting upstream of a leak.
The clinicians getting consistent results are the ones who do the diagnostic work first, then bring in the peptides as a precise lever rather than a hopeful guess.
Where to go deeper
Repair peptides are a starting point in clinical peptide therapy because they are accessible, well-tolerated for most patients, and produce visible results when matched to the right case. They are also the place where most foundational learning happens about dosing, cycling, and clinical reasoning.
A structured curriculum, mentorship, and a community of clinicians sharing case detail are what move a prescriber from anecdote to mastery in this category.
Related: Peptide Education for Practitioners.
Want expert eyes on your peptide protocols every month? Explore the Peptide University practitioner membership.
Continue the work
From perspective to clinical practice
The frameworks in this article are taught in depth inside our Certification curriculum and refined every week inside the Inner Circle.
